# Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

> **NCT02566369** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 1208 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** CD5789 (trifarotene) 50μg/g cream
- **DRUG:** Placebo cream

## Key facts

- **NCT ID:** NCT02566369
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-30
- **Primary completion:** 2017-11-14
- **Final completion:** 2017-11-14
- **Target enrollment:** 1208 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566369, "Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02566369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*